In contrast, significant tumor growth inhibition was observed in mice treated with the combination of αPD-L1 and RdB/IL12/GMCSF, RdB/IL12/shVEGF, RdB/IL12/DCN, RdB/IL12/GMCSF-TK, or RdB/IL12/GMCSF-RLX, showing 100.0%, 95.1%, 70.1%, 36.3% and 99.5% reduction in tumor burden compared to the respective oncolytic adenovirus at 31 days after initial treatment (*P < 0.5, **P < 0.01), respectively. This evidence concerns the gene CSF2 and neoplasm.